A multicenter¸open label phase II trial of liposomal doxorubicin (LD) and docetaxel (DX), followed by concurrent chemotherapy and radiation therapy in locally advanced high risk, early breast cancer (HRBC). A multicenter¸open label phase II trial of liposomal doxorubicin (LD) and docetaxel (DX), followed by concurrent chemotherapy and radiation therapy in locally advanced high risk, early breast cancer (HRBC). J Clin Oncol 30: 2012 (ASCO MEETING ABSTRACTS May 30, 2012:e11041 ASCO MEETING ABSTRACTS May 30, 2012:e11041 / Recchia, F; Candeloro, G; Cesta, A; Desideri, Giovambattista; Necozione, S; Rea, Silvio. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 30:(2012).
A multicenter¸open label phase II trial of liposomal doxorubicin (LD) and docetaxel (DX), followed by concurrent chemotherapy and radiation therapy in locally advanced high risk, early breast cancer (HRBC). A multicenter¸open label phase II trial of liposomal doxorubicin (LD) and docetaxel (DX), followed by concurrent chemotherapy and radiation therapy in locally advanced high risk, early breast cancer (HRBC). J Clin Oncol 30: 2012 (ASCO MEETING ABSTRACTS May 30, 2012:e11041 ASCO MEETING ABSTRACTS May 30, 2012:e11041
DESIDERI, GIOVAMBATTISTA;REA, Silvio
2012
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
